ALX Oncology Holdings Inc (ALXO): Cash & Equivalents
$16.37M
As of 2025-12-31
$22.69M
As of 2026-06-30
-30.5%
3-year compound annual growth
-48.1%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $16.37M | -6.8% | 2026-03-09, Balance as of period end |
| 2024-12-31 | $17.57M | -21.6% | 2026-03-09, Balance as of period end |
| 2023-12-31 | $22.41M | -54.1% | 2026-03-09, Balance as of period end |
| 2022-12-31 | $48.82M | -86.6% | 2025-03-06, Balance as of period end |
| 2021-12-31 | $363.67M | -16.2% | 2024-03-07, Balance as of period end |
| 2020-12-31 | $434.22M | n/m | 2023-03-09, Balance as of period end |
| 2019-12-31 | $9.02M | n/a | 2021-03-18, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| ALX Oncology Holdings Inc (ALXO) | 2025-12-31 | $16.37M | -6.8% |
| Scynexis Inc (SCYX) | 2025-12-31 | $21.26M | +32.4% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $18.62M | +394.9% |
| Biomea Fusion, Inc. (BMEA) | 2025-12-31 | $55.81M | -4.2% |
| Palvella Therapeutics, Inc. (PVLA) | 2025-12-31 | $57.98M | -30.6% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $90.0K | -86.7% |
| Pasithea Therapeutics Corp. (KTTA) | 2025-12-31 | $55.16M | +696.8% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $10.71M | -31.6% |
| DiaMedica Therapeutics Inc. (DMAC) | 2025-12-31 | $15.65M | +417.3% |
Compare ALXO, SCYX, RANI, BMEA side by side · Screen every company in Pharmaceutical Preparations ↗